Genomics of myelodysplastic/myeloproliferative neoplasm
Myelodysplastic/ Myeloproliferative neoplasms (MDS/MPN) demonstrate overlapping pathologic and molecular features of myelodysplastic (MDS) and myeloproliferative (MPN) neoplasms.
Myelodysplastic Syndromes (MDS)
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study
Original Publication Date
Article Source
External Web Content
Key Points In MDS, health-related quality of life (HRQoL) was worse for vulnerable participants and those with worse prognosis. Lower-risk MDS was associated with better HRQoL, but this relationship was lost among the vulnerable. Health-related quality of life (HRQoL) and…
What is the IPSS-M for MDS?
Topic(s)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Gail J. Roboz, M.D.
In this webinar, Dr. Gail Roboz discusses the Molecular International Prognostic Scoring System (IPSS-M) which is a newly developed risk stratification model for myelodysplastic syndromes (MDS) that expands on the original IPSS-R by including data on somatic oncogenic mutations…
Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings
Two articles in this week’s issue focus on the use of ipilimumab and decitabine decitabine: It works by reducing the amount of methylation in the body.
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
Background: Older patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PLASS-ti